Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Pazdur's Opdivo Love Affair And Other Adventures

This article was originally published in Scrip

Executive Summary

This year's Biopharma Congress conference in Washington had something for everyone – debates on the current drug pricing atmosphere, discussions about what's missing in the House-passed 21st Century Cures Act that may be included in the Senate's version of the legislation and an update about the status of those pending FDA biosimilars guidances, which was essentially to confirm they're still pending.


Related Content

Kite’s Axi-Cel CAR-T: No Adcomm, No Problem


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts